BMRN (STOCKS)
BioMarin Pharmaceuticals Inc
$55.650000
-0.300000 (-0.54%)
Prev close: $55.950000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Alexander Hardy
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $10,760.14M
- Employees
- 3,040
- P/E (TTM)
- 40.82
- P/B (TTM)
- 1.74
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
11
Strong Buy
16
Buy
7
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$0.54 | $0.77 | -0.2256 | -29.47% |
|
Dec 2025 (Q4)
|
$-0.24 | $0.64 | -0.8770 | -137.68% |
|
Sep 2025 (Q3)
|
$-0.16 | $0.38 | -0.5393 | -142.18% |
|
Jun 2025 (Q2)
|
$1.23 | $0.85 | +0.3784 | +44.43% |
Financial Statements
| Revenues | $3.24B |
| Benefits Costs and Expenses | $2.86B |
| Cost Of Revenue | $760.88M |
| Costs And Expenses | $2.93B |
| Gross Profit | $2.48B |
| Operating Expenses | $2.17B |
| Selling, General, and Administrative Expenses | $1.21B |
| Research and Development | $942.00M |
| Other Operating Expenses | $19.02M |
| Operating Income/Loss | $315.23M |
| Income/Loss From Continuing Operations After Tax | $268.74M |
| Income/Loss From Continuing Operations Before Tax | $385.59M |
| Income Tax Expense/Benefit | $116.85M |
| Income Tax Expense/Benefit, Deferred | $29.53M |
| Net Income/Loss | $268.74M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $268.74M |
| Net Income/Loss Available To Common Stockholders, Basic | $268.74M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $1.40 |
| Diluted Earnings Per Share | $1.37 |
| Basic Average Shares | 576,584,000 |
| Diluted Average Shares | 587,295,000 |
| Assets | $8.59B |
| Current Assets | $4.61B |
| Inventory | $1.27B |
| Other Current Assets | $3.33B |
| Noncurrent Assets | $3.99B |
| Fixed Assets | $958.07M |
| Intangible Assets | $204.66M |
| Other Non-current Assets | $2.82B |
| Liabilities | $2.38B |
| Current Liabilities | $793.15M |
| Wages | $152.61M |
| Other Current Liabilities | $640.54M |
| Noncurrent Liabilities | $1.59B |
| Long-term Debt | $1.43B |
| Other Non-current Liabilities | $155.48M |
| Equity | $6.21B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $6.21B |
| Liabilities And Equity | $8.59B |
| Net Cash Flow From Operating Activities | $874.25M |
| Net Cash Flow From Operating Activities, Continuing | $874.25M |
| Net Cash Flow From Investing Activities | $339.52M |
| Net Cash Flow From Investing Activities, Continuing | $339.52M |
| Net Cash Flow From Financing Activities | $809.55M |
| Net Cash Flow From Financing Activities, Continuing | $809.55M |
| Net Cash Flow | $2.02B |
| Net Cash Flow, Continuing | $2.02B |
| Comprehensive Income/Loss | $245.35M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $245.35M |
| Other Comprehensive Income/Loss | $245.35M |
| Other Comprehensive Income/Loss Attributable To Parent | -$23.39M |